Sarepta Therapeutics (NASDAQ:SRPT) Stock Keeps “Sell” Rating at HC Wainwright

HC Wainwright reissued their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Monday morning, MarketBeat Ratings reports. HC Wainwright currently has a $5.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on SRPT. Zacks Research raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. cut their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, September 30th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, July 9th. Benchmark reiterated a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, September 9th. Finally, Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and seven have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $22.71.

Sarepta Therapeutics Price Performance

Shares of SRPT stock opened at $17.49 on Monday. The stock’s 50-day moving average is $19.02 and its 200 day moving average is $18.82. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $25.32. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. The company has a market cap of $1.85 billion, a P/E ratio of -6.03, a PEG ratio of 0.27 and a beta of 0.38.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business had revenue of $401.25 million during the quarter, compared to analyst estimates of $366.39 million. During the same period in the prior year, the firm posted $2.02 earnings per share. The company’s quarterly revenue was down 34.3% on a year-over-year basis. Research analysts predict that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 7.8% during the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 636 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of Sarepta Therapeutics by 3.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 875 shares during the period. Baird Financial Group Inc. grew its stake in Sarepta Therapeutics by 7.6% during the 2nd quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock worth $230,000 after buying an additional 901 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Sarepta Therapeutics during the 2nd quarter worth approximately $27,000. Finally, Rockefeller Capital Management L.P. increased its position in Sarepta Therapeutics by 98.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock worth $88,000 after buying an additional 2,034 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.